Beyond the PhD is excited to welcome Dr. Jayendra Kumar Krishnaswamy, a cellular immunologist and Principal Scientist at Galderma. Come learn about his career path on Friday March 24th at 3pm ET (zoom). Free Event!
Register here: https://lnkd.in/et6m634T
Dr. Jayendra Kumar Krishnaswamy’s Bio:
I am a cellular immunologist with over 15 years of experience in both academia and industry. My research interests are primarily in innate-adaptive immune cell cross-talk in the context of autoimmunity, inflammatory diseases and vaccine responses. I did my PhD at the Hannover Biomedical Research School in Germany where I worked on targeting lung dendritic cells to tailor T cell responses. I did my post-doctoral training at Yale with Prof. Stephanie Eisenbarth where we delineated the role of conventional dendritic cell subsets in driving humoral responses. Specifically, we identified that Type 2 conventional DCs drove T follicular helper cell responses by carrying antigen to a unique sub-anatomic region of the lymph node- the T-B border. My expertise in DC-T cell cross-talk as well as experience in respiratory immunology led to a position as Senior Research Scientist at AstraZeneca, Sweden. My work at AstraZeneca primarily focused on identifying novel therapeutic targets for respiratory, inflammation and autoimmune diseases like asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. I also led an independent research group with postdoctoral and graduate students, where we delineated the role of human dendritic cell and tissue resident memory cells in the context of inflammatory diseases. In order to better understand the drug discovery process, I joined a smaller mid-size company, Galderma as a Principal Scientist. Galderma is focused on I worked in the pre-clinical research team where we were leading several projects into the clinic. However, within a few months after joining, the leadership at Galderma noticed my affinity for working with omics datasets as well as unearthing molecular and cellular responses. I was asked to setup and lead a Translational Medicine team, which I have been doing for the past 2.5 years. My team is responsible for mechanism of Action (MOA) and biomarker identification for all pipeline projects, i.e preclinical to Phase III, within multiple disease indications including Atopic dermatitis, Prurigo Nodularis (PN), Acne and Cutaneous T cell Lymphoma. During this time, we have successfully led biomarker analysis for multiple Phase II and Phase III studies, described the MOA of a marketed product in acne, as well as the MOA of a clinical stage asset in Prurigo Nodularis- all with state-of-the art multi-omics analyses. We also work with multiple research partners in academia and industry, publish extensively as well as present our work at various international conferences.
